Syntax Research, Inc. Crispr Therapeutics Ag Transaction History
Syntax Research, Inc.
- $139 Billion
- Q4 2024
A detailed history of Syntax Research, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Syntax Research, Inc. holds 250 shares of CRSP stock, worth $12,430. This represents 0.01% of its overall portfolio holdings.
Number of Shares
250
Previous 250
-0.0%
Holding current value
$12,430
Previous $11.7 Million
16.22%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
494Shares Held
64.3MCall Options Held
1.68MPut Options Held
1.95M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$446 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$435 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$190 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$138 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$137 Million1.21% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.88B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....